RZL-012 + celecoxib + cetirizine

RZL-012 is a novel investigational small molecule drug (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) developed for subcutaneous injection to reduce localized fat tissue in conditions such as Dercum disease and for aesthetic fat reduction. Its mechanism of action involves direct disruption of adipocyte cell membrane integrity, leading to adipocyte death (liponecrosis), followed by an inflammatory response and replacement of dead fat with fibrotic tissue, resulting in contraction and reduction of the treated area’s fat volume[1][6][8]. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase 2 (COX2), reducing inflammation and pain. Cetirizine is a second-generation antihistamine that acts as an antagonist at the histamine H1 receptor, used primarily for allergy symptom relief. The combination described here refers to their concurrent use in clinical trials involving RZL-012; celecoxib and cetirizine are administered orally as supportive medications to manage potential side effects or enhance tolerability during treatment with RZL‑012[4].

Brand names

None

Other names

None